Sign up Australia
Proactive Investors - Run By Investors For Investors

Living Cell Technologies files patent for neurological agent

The technology could reverse human brain neurodegenerative processes.
neural pathways
Identifying neuroprotective product candidates

Living Cell Technologies Ltd (ASX:LCT) has filed a provisional patent for pericyte (a type of cell) protective agents for neurological disorders including neurodegenerative and central nervous system diseases.

The invention in this provisional patent arises from Living Cell’s research collaboration with the Centre for Brain Research (CBR) at The University of Auckland.

The research collaboration explored how the company’s products can reverse human brain neurodegenerative processes associated with pericytes (and other brain cells).

Living Cell’s lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.

After implantation, NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

The company is aiming to extend the pipeline for NTCELL by examining its effects on cell cultures derived from human brains with Alzheimer’s disease and Parkinson’s disease.

The filing of the new patent will enable Living Cell to build and extend its expertise on the efficacy of cell therapies which have the potential to treat neurodegenerative disorders.

Critically, the ability to generate data from human brain tissue cultures can potentially lead the company to identify neuroprotective product candidates.





Register here to be notified of future LCT Company articles
View full LCT profile View Profile

Living Cell Technologies Ltd Timeline

Related Articles

scientist in a lab
September 28 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
hepatitisC.jpg
July 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
test tubes filled with blood
November 03 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use